Entest BioMedical Inc. (ENTB) Financials Nov 14, 2014, 8:10 p.m.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Entest BioMedical Inc.
Fiscal year is September-August. All values USD millions. 2009 2010 2011 2012 2013 5-year trend
Sales/Revenue 0 0 349,141 426,252 0
Cost of Goods Sold (COGS) incl. D&A 0 0 89,405 119,299 -
COGS excluding D&A 0 0 89,405 110,062 -
Depreciation & Amortization Expense 0 - - 9,237 2,843
Depreciation 0 0 0 8,461 2,073
Amortization of Intangibles 0 0 0 776 770
Gross Income 0 0 259,736 306,953 -
2009 2010 2011 2012 2013 5-year trend
SG&A Expense 245,437 537,816 1.17M 1.12M 660,154
Research & Development 10,000 20,933 109,063 5,798 0
Other SG&A 235,437 516,883 1.06M 1.12M 660,154
Other Operating Expense 78 0 0 0 0
Unusual Expense 0 0 0 701,980 490,906
EBIT after Unusual Expense 0 0 0 (701,980) (490,906)
Non Operating Income/Expense 0 0 99 38,418 42,389
Non-Operating Interest Income 0 - - 0 0
Equity in Affiliates (Pretax) 0 0 0 - 0
Interest Expense 0 7,075 40,832 409,880 182,069
Gross Interest Expense 0 7,075 40,832 409,880 182,069
Interest Capitalized 0 0 0 0 0
Pretax Income (245,515) (544,891) (951,783) (1.89M) (1.29M)
Income Tax 0 0 0 0 0
Income Tax - Current Domestic 0 0 0 - -
Income Tax - Current Foreign 0 0 0 - -
Income Tax - Deferred Domestic 0 0 0 - -
Income Tax - Deferred Foreign 0 0 0 - -
Income Tax Credits 0 0 0 - -
Equity in Affiliates 0 0 0 0 0
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income (245,515) (544,891) (951,783) (1.89M) (1.29M)
Minority Interest Expense 0 0 0 0 0
Net Income (245,515) (544,891) (951,783) (1.89M) (1.29M)
Extraordinaries & Discontinued Operations 0 0 0 0 (34,554)
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations 0 0 0 0 (34,554)
Net Income After Extraordinaries (245,515) (544,891) (951,783) (1.89M) (1.33M)
Preferred Dividends 0 0 0 32,142 0
Net Income Available to Common (245,515) (544,891) (951,783) (1.92M) (1.29M)
EPS (Basic) (0.11) (0.03) (0.05) (0.02) ()
Basic Shares Outstanding 2.25M 17.54M 19.9M 94.99M 458.31M
EPS (Diluted) (0.11) (0.03) (0.05) (0.02) ()
Diluted Shares Outstanding 2.25M 17.54M 19.9M 94.99M 458.31M
EBITDA (245,515) (537,816) - (806,884) (660,154)
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Entest BioMedical Inc.
Fiscal year is September-August. All values USD millions. 2009 2010 2011 2012 2013 5-year trend
Sales/Revenue 0 0 349,141 426,252 0
Cost of Goods Sold (COGS) incl. D&A 0 0 89,405 119,299 -
COGS excluding D&A 0 0 89,405 110,062 -
Depreciation & Amortization Expense 0 - - 9,237 2,843
Depreciation 0 0 0 8,461 2,073
Amortization of Intangibles 0 0 0 776 770
Gross Income 0 0 259,736 306,953 -
2009 2010 2011 2012 2013 5-year trend
SG&A Expense 245,437 537,816 1.17M 1.12M 660,154
Research & Development 10,000 20,933 109,063 5,798 0
Other SG&A 235,437 516,883 1.06M 1.12M 660,154
Other Operating Expense 78 0 0 0 0
Unusual Expense 0 0 0 701,980 490,906
EBIT after Unusual Expense 0 0 0 (701,980) (490,906)
Non Operating Income/Expense 0 0 99 38,418 42,389
Non-Operating Interest Income 0 - - 0 0
Equity in Affiliates (Pretax) 0 0 0 - 0
Interest Expense 0 7,075 40,832 409,880 182,069
Gross Interest Expense 0 7,075 40,832 409,880 182,069
Interest Capitalized 0 0 0 0 0
Pretax Income (245,515) (544,891) (951,783) (1.89M) (1.29M)
Income Tax 0 0 0 0 0
Income Tax - Current Domestic 0 0 0 - -
Income Tax - Current Foreign 0 0 0 - -
Income Tax - Deferred Domestic 0 0 0 - -
Income Tax - Deferred Foreign 0 0 0 - -
Income Tax Credits 0 0 0 - -
Equity in Affiliates 0 0 0 0 0
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income (245,515) (544,891) (951,783) (1.89M) (1.29M)
Minority Interest Expense 0 0 0 0 0
Net Income (245,515) (544,891) (951,783) (1.89M) (1.29M)
Extraordinaries & Discontinued Operations 0 0 0 0 (34,554)
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations 0 0 0 0 (34,554)
Net Income After Extraordinaries (245,515) (544,891) (951,783) (1.89M) (1.33M)
Preferred Dividends 0 0 0 32,142 0
Net Income Available to Common (245,515) (544,891) (951,783) (1.92M) (1.29M)
EPS (Basic) (0.11) (0.03) (0.05) (0.02) ()
Basic Shares Outstanding 2.25M 17.54M 19.9M 94.99M 458.31M
EPS (Diluted) (0.11) (0.03) (0.05) (0.02) ()
Diluted Shares Outstanding 2.25M 17.54M 19.9M 94.99M 458.31M
EBITDA (245,515) (537,816) - (806,884) (660,154)
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
